Fig. 1 · Structure

Documents & Downloads

Pictilisib dimethanesulfonate

Cat. No. A11444 CAS 957054-33-0

PI3Kα/δ inhibitor

Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
p110α IC50 3 nM
p110α-H1047R IC50 3 nM
p110α-E545K IC50 3 nM
p110δ IC50 3 nM
p110β IC50 33 nM
p110γ IC50 75 nM
mTOR Ki 0.58 μM
DNA-PK IC50 1.23 μM
Autophagy  

9 targets · Scroll to view more

Pictilisib dimethanesulfonate Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Pictilisib dimethanesulfonate from 2 published references. In vitro models include AR + TNBC cells; OVSAHO.

Pictilisib dimethanesulfonate In Vitro Studies

AR-positive TNBC cells treated with Pictilisib dimethanesulfonate for 72 h were significantly more sensitive than the other cell lines, with inhibitory concentrations of 680 nM versus 2044 nM. In OVSAHO cells, treatment at 5 µM in complete medium for 7 days produced a moderate reduction in cell viability. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

AR-positive TNBC cells show greater sensitivity to Pictilisib

Cell-based study · AR + TNBC cells [1]

AR + TNBC cells were significantly more sensitive to GDC-0941 (680 nM versus 2044 nM, P = 0.01) compared to the other cell lines.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% inhibitory concentration (EC50)EC50 680 nM versus 2044 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM-3000 nM
Exposure duration
72 h
Method
media containing half-log serial dilutions
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pictilisib dimethanesulfonate; Compound label in the paper: GDC-0941

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cell proliferation/viability assays and inhibitory concentration of 50% (EC50) determination (S39, S40); Results > LAR TNBC cell lines stimulated by dihydrotestosterone have increased PI3K pathway activity and are sensitive to PI3K/TOR pathway inhibitors (S97); Figure 3 legend (S151)

50% inhibitory concentration (EC50): 50% inhibitory concentration (EC50); comparator: the other cell lines — Results > LAR TNBC cell lines stimulated by dihydrotestosterone have increased PI3K pathway activity and are sensitive to PI3K/TOR pathway inhibitors (S97); Figure 3 legend (S151)

Pictilisib moderately reduces OVSAHO cell viability

Cell-based study · OVSAHO [2]

OVSAHO cells were treated with Pictilisib dimethanesulfonate at 5 µM in complete medium for 7 days. Treatment produced a moderate reduction in cell viability.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Clonogenic survivalReported result Pictilisib, 5 µM; 7 days; in complete medium: moderate reduction in cell viability.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
7 days
Method
in complete medium
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Pictilisib dimethanesulfonate; Compound label in the paper: Pictilisib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell viability assays (S57, S58); Results > PI3K inhibition triggers lethal vacuolization in serum-starved cancer cells with sustained macropinocytosis (S104, S107, S112)

Clonogenic survival: Clonogenic survival; comparator: treated with or without Pictilisib — Results > PI3K inhibition triggers lethal vacuolization in serum-starved cancer cells with sustained macropinocytosis (S104, S107, S112)

Pictilisib dimethanesulfonate In Vivo Studies

SNU119 xenograft-bearing BALB/c nude mice received Pictilisib dimethanesulfonate at 120 mg/kg by oral gavage once daily for 21 days under ad libitum feeding conditions. Compared with the ad libitum feeding control, treatment significantly inhibited tumor growth (TGI of 68%; p < 0.001). [2]

Tumor growth inhibition under ad libitum feeding

Animal study · Eight-week-old female BALB/c nude mice; SNU119 xenograft-bearing mice; Pictilisib + AL, n = 9 [2]

SNU119 xenograft-bearing BALB/c nude mice received Pictilisib dimethanesulfonate at 120 mg/kg by oral gavage once daily for 21 days under ad libitum feeding conditions. Compared with the ad libitum feeding control, treatment significantly inhibited tumor growth (TGI of 68%; p < 0.001).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growthtumor growth inhibition TGI of 68%[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
once daily; 21 days
Vehicle
0.5% methylcellulose/0.2% Tween 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pictilisib dimethanesulfonate 120 mg/kgAL, n = 8Pictilisib under AL conditions significantly inhibited tumor growth (TGI of 68%; p < 0.001)[2]
Pictilisib dimethanesulfonate 120 mg/kg
Model: Eight-week-old female BALB/c nude mice; SNU119 xenograft-bearing mice; Pictilisib + AL, n = 9
Methods and source locations

Compound reported in the paper: Pictilisib dimethanesulfonate; Compound label in the paper: Pictilisib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > In vivo mouse xenograft study (S81, S83, S86); Results > Pictilisib synergizes with dietary restriction to induce methuosis in vivo (S247, S248, S249, S255, S257)

Tumor growth: Tumor growth; comparator: AL, n = 8 — Results > Pictilisib synergizes with dietary restriction to induce methuosis in vivo (S248, S249)

Pictilisib dimethanesulfonate 120 mg/kg · Materials and methods > In vivo mouse xenograft study (S86); Results > Pictilisib synergizes with dietary restriction to induce methuosis in vivo (S249, S255)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 957054-33-0
Applications PI3Kα/δ inhibitor
Formula C25H35N7O9S4
Molecular Weight 705.85
Synonyms GDC-0941 dimethanesulfonate; GDC-0941 2 MeSO3H salt
SMILES
O=S(N1CCN(CC1)CC2=CC3=C(S2)C(N4CCOCC4)=NC(C5=CC=CC6=C5C=NN6)=N3)(C)=O.O=S(O)(C)=O.O=S(O)(C)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Pictilisib dimethanesulfonate Research References

  1. [1] Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res (2014). PMID: 25103565 DOI: 10.1186/s13058-014-0406-x Source material
  2. [2] Wang X, Sang X, Wen Y, et al. Pictilisib and nutrient stress synergize to induce methuosis via PI(4,5)P2-dependent macropinocytic dysregulation in cancer cells. Cell Death Dis (2026). PMID: 42303628 DOI: 10.1038/s41419-026-08994-6 Source material

Added to your cart

View Cart Checkout
Loading...